IKT
Inhibikase Therapeutics Inc
2.00$
+2.9%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -18.9% | -23.7% | -20.3% | -50.4% | +2,152.7% | -4.4% | -5.8% | -10.4% | +127.7% | -4.3% | -5.6% | |
| – | -19.0% | -23.9% | -20.4% | -51.3% | +2,249.6% | -4.4% | -5.7% | -11.6% | +129.3% | -4.4% | -5.7% | |
| – | -38.3% | -74.3% | +31.2% | -70.4% | +6,084.5% | +30.0% | +5.9% | -50.8% | +263.8% | -64.4% | -37.0% | |
| – | -21.3% | -26.4% | -18.6% | -59.1% | +2,907.2% | -4.5% | -5.9% | -11.8% | +131.2% | -4.7% | -6.7% | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +23.3% | +21.6% | -13.1% | +31.6% | -23.9% | +129.0% | +2.9% | -23.9% | +24.0% | -31.2% | +79.6% | |
| – | +25.4% | +23.1% | -12.5% | +32.5% | -23.9% | +129.0% | +2.9% | -23.9% | +24.0% | -31.2% | +79.6% | |
| – | +256.9% | -18.8% | -23.7% | -34.2% | -49.0% | -32.3% | -49.3% | – | – | – | – | |
| – | -12.0% | +100.0% | +3.6% | +88.7% | -62.7% | +79.4% | +59.8% | -77.0% | +86.6% | +37.1% | -37.5% | |
| – | -26.9% | -38.3% | -24.8% | -110.4% | – | -9.6% | -6.6% | -8.9% | +137.2% | -3.1% | -8.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +15.8% | +2.5% | +18.8% | +17.9% | +83.5% | +449.4% | +0.5% | +0.0% | +4.6% | +83.0% | +1.3% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.